Navigation Links
Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
Date:11/11/2008

EMERYVILLE, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced that Isaac Cohen, Chairman and CEO of Bionovo, will be presenting an overview of the Company at the Rodman & Renshaw 10th Annual Global Investment Conference on November 11, 2008 at 5:45 p.m. Eastern Time. The event will be held at the New York Palace Hotel in New York City.

The presentation will be webcast and can be viewed via Bionovo's website at http://bionovo.com/investors/events. A webcast replay will become available shortly after the presentation ends and will continue to be accessible for 90 days via Bionovo's website.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. John D. Baxter, M.D. Joins Bionovos Board of Directors
2. Bionovo to Present at the Cambria Capital Investor Meeting
3. Bionovo Announces 2007 Financial Results and Highlights
4. Bionovo Describes a New Class of Therapeutic Compounds
5. Bionovo Announces Closing of Public Offering of Common Stock
6. ProAssurance to Present at Oppenheimer Investor Conference
7. Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations
8. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
9. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
10. Wyeth to Present at the Credit Suisse Healthcare Conference
11. Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Jericho Project has named LaToya Williams-Belfort to ... be responsible for fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO ... working to end homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error ... NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause ... error will ever be totally eliminated, many human performance problems can be prevented. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has ... and expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the ... event photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence ... practice enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a ... Orion location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
Breaking Medicine Technology: